DAIICHI SANKYO, INC. for DAIICHI SANKYO INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding the Omnibus Spending Bill (H.R.1 - PL 115-97)
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Medicare/Medicaid MMM
Discussions regarding Medicare, IPAB, and Part D and Part B
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Pharmacy PHA
Discussions regarding opioid abuse Discussions regarding 340B drug discount program S.974,Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act of 2017) Discussions regarding PBM patient assistance limitations
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.